With the improvement of metabolic disorder and hyperandrogenemia, the level of circulating adipoq was found to increase significantly in all three treatment groups, but a significant decrease in serum HHIP levels was observed only in the TZDs and GLP-1RA groups. This evidence concerns the gene HHIP and Other metabolic disease.